Progress in understanding of relationship between ceramide and cardiovascular disease

doi:10.3877/cma.j.issn.1674-0785.2023.11.011

Abstract

Abstract:

Cardiovascular disease (CVD) is a major category of diseases threatening human health and life. Ceramide is a simple bioactive sphingolipid that plays a role in the pathogenesis of diabetes and CVD. Ceramide has been shown to accumulate in many tissues of individuals with CVD, including the vascular system and the heart. In recent years, more and more studies have shown that ceramide is closely related to a variety of CVDs. Ceramide is involved in the occurrence and development of CVD, and has predictive value especially for hypertension, coronary atherosclerotic heart disease, and heart failure. Future studies are needed to confirm whether reducing ceramide levels and the reactive enzymes involved in ceramide synthesis pathways can reduce the severity and risk of serious outcomes in CVD.

Key words: Ceramide, Cardiovascular disease, Hypertension, Heart failure, Coronary atherosclerotic heart disease

Hong Zhang, Hongyu Wang. Progress in understanding of relationship between ceramide and cardiovascular disease[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(11): 1202-1205.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2023.11.011

https://zhlcyszz.cma-cmc.com.cn/EN/Y2023/V17/I11/1202

References 49

1	Summers SA, Chaurasia B, Holland WL. Metabolic messengers: ceramides [J]. Nat Metab, 2019, 1(11): 1051-1058.
2	Rivera IG, Ordoñez M, Presa N, et al. Sphingomyelinase D/ceramide 1-phosphate in cell survival and inflammation [J]. Toxins (Basel), 2015, 7(5): 1457-1466.
3	Chang KT, Anishkin A, Patwardhan GA, et al. Ceramide channels: destabilization by Bcl-xL and role in apoptosis [J]. Biochim Biophys Acta, 2015, 1848(10 Pt A): 2374-2384.
4	Stith JL, Velazquez FN, Obeid LM. Advances in determining signaling mechanisms of ceramide and role in disease [J]. J Lipid Res, 2019, 60(5): 913-918.
5	Mantovani A, Dugo C. Ceramides and risk of major adverse cardiovascular events: A meta-analysis of longitudinal studies [J]. J Clin Lipidol, 2020, 14(2): 176-185.
6	Alexaki A, Clarke BA, Gavrilova O, et al. De Novo sphingolipid biosynthesis is required for adipocyte survival and metabolic homeostasis [J]. J Biol Chem, 2017, 292(9): 3929-3939.
7	Peters L, Kuebler WM, Simmons S. Sphingolipids in atherosclerosis: Chimeras in structure and function [J]. Int J Mol Sci, 2022, 23(19): 11948.
8	Hadas Y, Vincek AS, Youssef E, et al. Altering sphingolipid metabolism attenuates cell death and inflammatory response after myocardial infarction [J]. Circulation, 2020, 141(11): 916-930.
9	Ouro A, Correa-Paz C, Maqueda E, et al. Involvement of ceramide metabolism in cerebral ischemia [J]. Front Mol Biosci, 2022, 9: 864618.
10	Poss AM, Maschek JA, Cox JE, et al. Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease [J]. J Clin Invest, 2020, 130(3): 1363-1376.
11	Kikas P, Chalikias G, Tziakas D. Cardiovascular implications of sphingomyelin presence in biological membranes [J]. Eur Cardiol, 2018, 13(1): 42-45.
12	Laaksonen R, Ekroos K, Sysi-Aho M, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol [J]. Eur Heart J, 2016, 37(25): 1967-1976.
13	Havulinna AS, Sysi-Aho M, Hilvo M, et al. Circulating ceramides predict cardiovascular outcomes in the population-based Finrisk 2002 cohort [J]. Arterioscler Thromb Vasc Biol, 2016, 36(12): 2424-2430.
14	Peterson LR, Xanthakis V, Duncan MS, et al. Ceramide remodeling and risk of cardiovascular events and mortality [J]. J Am Heart Assoc, 2018, 7(10): e007931.
15	Timmerman N, Waissi F, Dekker M, et al. Ceramides and phospholipids in plasma extracellular vesicles are associated with high risk of major cardiovascular events after carotid endarterectomy [J]. Sci Rep, 2022, 12(1): 5521.
16	Summers SA. Editorial: The role of ceramides in diabetes and cardiovascular disease [J]. Front Endocrinol (Lausanne), 2021, 12: 667885.
17	Wang DD, Toledo E, Hruby A, et al. Plasma ceramides, mediterranean diet, and incident cardiovascular disease in the predimed trial (prevención con dieta mediterránea) [J]. Circulation, 2017, 135(21): 2028-2040.
18	Mohamud Yusuf A, Hagemann N, Hermann DM. The acid sphingomyelinase/ceramide system as target for ischemic stroke therapies [J]. Neurosignals, 2019, 27(S1): 32-43.
19	Peters L, Kuebler WM, Simmons S. Sphingolipids in atherosclerosis: Chimeras in structure and function [J]. Int J Mol Sci, 2022, 23(19): 11948.
20	Borodzicz-Jażdżyk S, Jażdżyk P, Łysik W, et al. Sphingolipid metabolism and signaling in cardiovascular diseases [J]. Front Cardiovasc Med, 2022, 9: 915961.
21	Cheng JM, Suoniemi M, Kardys I, et al. Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study [J]. Atherosclerosis, 2015, 243(2): 560-566.
22	You Q, Peng Q, Yu Z, et al. Plasma lipidomic analysis of sphingolipids in patients with large artery atherosclerosis cerebrovascular disease and cerebral small vessel disease [J]. Biosci Rep, 2020, 40(9): BSR20201519.
23	Spijkers LJ, van den Akker RF, Janssen BJ, et al. Hypertension is associated with marked alterations in sphingolipid biology: a potential role for ceramide [J]. PLoS One, 2011, 6(7): e21817.
24	Zhang DX, Zou AP, Li PL. Ceramide-induced activation of NADPH oxidase and endothelial dysfunction in small coronary arteries [J]. Am J Physiol Heart Circ Physiol, 2003, 284(2): H605-H612.
25	Li H, Junk P, Huwiler A, et al. Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase [J]. Circulation, 2002, 106(17): 2250-2256.
26	Cogolludo A, Villamor E, Perez-Vizcaino F, et al. Ceramide and regulation of vascular tone [J]. Int J Mol Sci, 2019, 20(2): 411.
27	Fenger M, Linneberg A, Jørgensen T, et al. Genetics of the ceramide/sphingosine-1-phosphate rheostat in blood pressure regulation and hypertension [J]. BMC Genet, 2011, 12: 44.
28	Yin W, Li F, Tan X, et al. Plasma ceramides and cardiovascular events in hypertensive patients at high cardiovascular risk [J]. Am J Hypertens, 2021, 34(11): 1209-1216.
29	Ji R, Akashi H, Drosatos K, et al. Increased de novo ceramide synthesis and accumulation in failing myocardium [J]. JCI Insight, 2017, 2(14): e96203.
30	Basu R, Oudit GY, Wang X, et al. Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function [J]. Am J Physiol Heart Circ Physiol, 2009, 297(6): H2096-H2108.
31	Shu H, Peng Y, Hang W, et al. Emerging roles of ceramide in cardiovascular diseases [J]. Aging Dis, 2022, 13(1): 232-245.
32	Hoffman M, Palioura D, Kyriazis ID, et al. Cardiomyocyte Krüppel-Like factor 5 promotes De Novo ceramide biosynthesis and contributes to eccentric remodeling in ischemic cardiomyopathy [J]. Circulation, 2021, 143(11): 1139-1156.
33	Reforgiato MR, Milano G, Fabriàs G, et al. Inhibition of ceramide de novo synthesis as a postischemic strategy to reduce myocardial reperfusion injury [J]. Basic Res Cardiol, 2016, 111(2): 12.
34	Jeffrey W, Meeusen, Leslie J, et al. Plasma ceramides [J]. Arterioscler Thromb Vasc Biol, 2018, 38(8): 1933-1939.
35	Butler TJ, Ashford D, Seymour AM. Western diet increases cardiac ceramide content in healthy and hypertrophied hearts [J]. Nutr Metab Cardiovasc Dis, 2017, 27(11): 991-998.
36	张鹏, 陈夏欢, 王昊, 等. 神经酰胺在心血管疾病预测价值中的研究进展 [J]. 中国心血管杂志, 2020, 25(2): 189-192.
37	刘潇, 王雷. 神经酰胺与心血管疾病关系的研究进展 [J]. 临床和实验医学杂志, 2020, 19(15): 1668-1671.
38	Choi RH, Tatum SM, Symons JD, et al. Ceramides and other sphingolipids as drivers of cardiovascular disease [J]. Nat Rev Cardiol, 2021, 18(10): 701-711.
39	Zietzer A, Düsing P, Reese L, et al. Ceramide metabolism in ccardiovascular disease: a network with high therapeutic potential [J]. Arterioscler Thromb Vasc Biol, 2022, 42(10): 1220-1228.
40	Choi RH, Tatum SM, Symons JD, et al. Ceramides and other sphingolipids as drivers of cardiovascular disease [J]. Nat Rev Cardiol, 2021, 18(10): 701-711.
41	王宏宇, 刘欢. 推动心脏和血管健康规范化综合评估, 增强全民血管健康意识—《中国血管健康评估系统应用指南(2018第三次报告)》解读 [J]. 中华医学杂志, 2018, 98(37): 2953-2954.
42	Wen F, Liu Y, Wang H. Clinical evaluation tool for vascular health-endothelial function and cardiovascular disease management [J]. Cells, 2022, 11(21): 3363.
43	王宏宇, 陈新. 依托信息化的全生命周期血管健康管理与心血管疾病社区防治策略 [J]. 中国医师杂志, 2020, 22(9): 1281-1284.
44	王宏宇. 应重视北京血管健康分级法在智慧化数字心脏和血管健康医学模式实践中的作用 [J]. 中华医学杂志, 2023, 103(2): 6-11.
45	王宏宇. 推广血管健康理念, 促进血管医学专业发展 [J]. 中国循环杂志, 2018, 33(10): 1026-1028.
46	中国医药教育协会血管医学专业委员会. 中国非传统血管健康危险因素管理策略专家共识(2022第一次报告) [J]. 中华医学杂志, 2023, 103(4): 242-258.
47	蒋姗彤, 王宏宇. 基于北京血管健康分级指导的智能化全生命周期心脏和血管健康管理[J/OL]. 中华临床医师杂志(电子版), 2019, 13(11): 868-871.
48	王宏宇. 血管衰老临床检测技术—重视血管内皮功能的评价与 EndoFIND 研究启示 [J]. 中国心血管杂志, 2021, 26(5): 418-424
49	Liu H, Xie G, Huang W, et al. Rationale and design of a multicenter, randomized, patients-blinded two-stage clinical trial on effects of endothelial function test in patients with non-obstructive coronary artery disease (ENDOFIND) [J]. Int J Cardiol, 2021, 325: 16-22.

[1]	Ying Li, Shaoqing Pan, Mingyan Ding, Dandan Sun, Haibo Qu, Peipei Hou, Fang Zhu. Evaluation of left ventricular systolic function and synchrony in advanced atrioventricular block patients with heart failure with preserved ejection fraction after left bundle branch area pacing by real-time three-dimensional echocardiography [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(04): 430-436.
[2]	Xiya Jin, Xiaosong Huang, Cheng Tan, Qin Jiang, Fang Hou, Yaoyue Li, Bing Xu, Honghui Jia, Wenying Liu. Antenatal treatment of tacrolimus on pulmonary vascular remodeling in rat with experimental pathological model of congenital diaphragmatic hernia [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 428-436.
[3]	Chen Li, Weijia Zhang, Yaping Pan. Application and experience of the relationship between periodontitis and systematic diseases: Interpretation and enlightenment of the 2022 Joint Workshop by the EFP and WONCA Europe [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(05): 322-327.
[4]	Jianmei Li, Jingjuan Deng, Qian Yang. Safety and follow-up evaluation of the combined treatment of hepatocellular carcinoma with hepatic cirrhosis and portal hypertension [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 41-44.
[5]	Qikun Zhang, Fuchao Shang, Qi Li, Guangming Li, Menglong Wang. Survival benefit of combined splenectomy in patients with liver cancer complicated with portal hypertension after radical resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 613-618.
[6]	Rong He, Zhe Jia, Ke Zhang, Daijing Li, Meng Zhang, Li Jiang. Analysis of clinical efficacy of laparoscopic hepatectomy combined with Hassab's procedure for primary liver cancer complicated with portal hypertension based on propensity score matching [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(04): 376-383.
[7]	Haiyan Chen, Huimin Zhou, Jiaqi Cui. Moderate severe acute pancreatitis following transurethral cystoscopic holmium laser lithotripsy: report of one case [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(04): 461-463.
[8]	Yuyang Xu, Yunfu Lyu, Baochun Wang. Progress of surgical treatments for splenomegaly in patients with hepatitis B cirrhotic portal hypertension [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(04): 469-473.
[9]	Xiulan Xu, Jianjian Zhu. Clinical relationship between blood pressure variability and poor prognosis in patients with acute cerebral infarction and H-type hypertension [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2023, 13(04): 199-204.
[10]	Wei Liu, Min Zhang, Mei Ling Jie, Qunqun Yu, Na Zhou, Guangping Chen, Xiang Yang, Yali Chen, Meihua Liu. Effect of hospital-community integration pattern on management of hypertension [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(11): 1176-1180.
[11]	Linyang Yu, Meiying Wang, Jianbin Li, Xiaobin Lou, Siyuan Xie, Zhizhong Ma, Haiying Qi, Jia Li. Characteristics of pulmonary arterial pressure and cardiac morphology and function in children with pneumonia and right heart failure in a high altitude area [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 535-544.
[12]	Zhen Wang, Xiaoyue Yang, Kangkang Su, Chaoyang Wang, Shaojie Li, Shuxia Chen, Jian Gu. Progress in understanding of prognostic impact of beta-blockers on patients with heart failure and atrial fibrillation [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(04): 479-482.
[13]	Yanyan Liu, Wanjiang Zeng. Diagnosis and treatment of pheochromocytoma in pregnancy [J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2023, 12(04): 228-231.
[14]	Mingjie Zhang, Liping Liu, Chunxiang Li, Yujie Liu, Zhuoming Xu. Efficacy and safety of early nitric oxide inhalation therapy after congenital heart surgery [J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2023, 11(04): 210-215.
[15]	Jianghua Gong, Ningxiang Li, Jian Li, Feng Li, Li Tong, Hongli Xing, Xinxia. He. Changes and significance of serum NPY, 5-HT, and BDNF levels in patients with essential hypertension and insomnia [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(06): 582-590.

Please choose a citation manager

Content to export